Divis Laboratories logo

Divis Laboratories

DIVISLAB NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
2.5L Cr
Volatility
Moderate
P/E Ratio
83.94
EBITDA
₹3,948 Cr
Return on Equity
15.32%
Debt to Equity
0
Book Value
₹631.38
EPS
₹63.06
52W High
₹9,740
52W Low
₹5,647.5

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 39.0%

Weaknesses

2
  • Stock is trading at 14.6 times its book value
  • The company has delivered a poor sales growth of 8.67% over past five years.

Growth Rate

Revenue Growth
13.95% higher than 3Y
Net Income Growth
17.21% higher than 3Y
Cash Flow Change
65.64% lower than 3Y
ROE
4.64% lower than 3Y
ROCE
0.58% lower than 3Y
EBITDA Margin (Avg.)
4.36% lower than 3Y

AI Analysis — Bull vs Bear

6d ago
AI opinion · based on fundamentals
Risk medium

Divi's Laboratories has a market capitalisation of about Rs 2,54,107 crore and trades at a P/E of 87.3x and a P/B of 15.23x. TTM sales grew 16% and TTM profit grew 29%, both well ahead of the 5-year CAGRs of 9% for sales and 6% for profit. The company is almost debt-free, pays out 39% of profit as dividends and has a 10-year ROE of 18%, but its valuation is high compared with its long-term growth record.

Bull Case 7
  • Growth has picked up: TTM profit grew 29% and TTM sales grew 16%, compared with 5-year CAGRs of 6% and 9%. This suggests earnings are recovering from the post-COVID normalisation phase.
  • The company is almost debt-free. This gives it balance-sheet room to fund capacity expansion and custom synthesis projects without financial risk from borrowing.
  • Returns on equity have held steady: 18% over 10 years, 17% over 5 years and 17% last year. That shows consistent capital efficiency through a full business cycle.
  • ROE has improved from the 3-year average of 15% to 17% last year, which points to recovering profitability.
  • The dividend payout ratio is 39.0%. That is a steady distribution policy while still keeping most earnings for reinvestment.
  • The stock has returned 22% a year over 10 years and 37% a year over 3 years. This reflects long-term value creation for shareholders.
  • With a market cap of about Rs 2,54,107 crore, Divi's is one of India's largest API and custom synthesis players. Its scale supports long-term relationships with global innovator pharma clients.
Bear Case 7
  • A P/E of 87.3x is far above the company's 10-year profit CAGR of 9%. Current earnings alone do not justify the price, so the stock is relying on growth continuing to speed up.
  • The stock trades at 15.23x book value. That is a large premium with little margin of safety if growth or margins disappoint.
  • Over the past five years, sales grew only 8.67% a year and profit only 6% a year. That record is modest compared with the premium valuation.
  • The stock returned 69% in one year, while TTM profit grew 29%. Much of the gain came from the valuation multiple rising rather than from earnings, which increases the risk of the multiple falling back.
  • The dividend yield is only 0.31%. Even with a 39% payout, investors get very little income support at this price.
  • The 3-year ROE of 15% is below the 10-year average of 18%. Profitability has not yet fully returned to its historical peak.
  • Over 5 years the stock returned only 14% a year, well below its 3-year and 1-year returns. This shows how volatile and cyclical returns in API and custom synthesis stocks can be.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago
Neutral 1
  • ₹23.49 crore BSE block trade Sep 30

    About 24,994 Divis Laboratories shares traded on BSE at ₹9,400.00 each, worth ₹23.49 crore in total. This came from a real-time trade scanner and isn't yet confirmed by the exchange, which publishes official disclosures after market close.

TL;DR: There is only one news item for Divis Laboratories: an unconfirmed ₹23.49 crore block trade at ₹9,400 per share on Sep 30. It shows institutional-sized activity, but it isn't clear who bought or sold, so it doesn't point the stock up or down. With no fundamental news here, there's no way to judge whether the trend is improving or getting worse. Watch the official BSE bulk/block deal disclosures to see who the buyer and seller were, and the upcoming quarterly results for direction on custom synthesis and API demand.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,778
1,909
1,855
2,303
2,118
2,338
2,319
2,585
2,410
2,715
2,604
2,831
3,080
Expenses
1,274
1,430
1,366
1,572
1,496
1,622
1,576
1,699
1,681
1,827
1,714
1,897
1,825
Operating Profit
504
479
489
731
622
716
743
886
729
888
890
934
1,255
OPM %
28%
25%
26%
32%
29%
31%
32%
34%
30%
33%
34%
33%
41%
Other Income
81
86
95
79
79
106
82
86
119
145
14
155
64
Interest
0
1
0
2
0
1
0
1
3
8
6
6
6
Depreciation
93
95
95
95
97
99
99
107
112
113
118
120
133
PBT
492
469
489
713
604
722
726
864
733
912
780
963
1,180
Tax %
28%
26%
27%
25%
29%
29%
19%
23%
26%
24%
25%
22%
24%
Net Profit
356
348
358
538
430
510
589
662
545
689
583
751
902
EPS in Rs
13.41
13.11
13.49
20.27
16.2
19.21
22.19
24.94
20.53
25.95
21.96
28.29
33.98
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,115
3,776
4,064
3,891
4,946
5,394
6,969
8,960
7,768
7,845
9,360
10,560
11,230
Expenses
1,942
2,354
2,615
2,622
3,072
3,568
4,102
5,075
5,397
5,635
6,387
7,118
7,263
Operating Profit
1,173
1,423
1,450
1,269
1,874
1,826
2,867
3,885
2,370
2,210
2,973
3,442
3,967
OPM %
38%
38%
36%
33%
38%
34%
41%
43%
31%
28%
32%
33%
35%
Other Income
38
93
72
107
154
186
57
112
344
335
348
433
378
Interest
3
5
3
2
5
7
2
2
2
4
3
24
26
Depreciation
136
118
123
142
169
186
256
312
343
378
402
463
484
PBT
1,072
1,393
1,395
1,231
1,855
1,819
2,666
3,684
2,369
2,163
2,916
3,388
3,835
Tax %
21%
19%
24%
29%
27%
24%
26%
20%
23%
26%
25%
24%
—
Net Profit
852
1,126
1,060
877
1,353
1,377
1,984
2,960
1,823
1,600
2,191
2,568
2,925
EPS in Rs
32.07
42.41
39.95
33.04
50.96
51.85
74.75
112
68.69
60.27
82.53
96.73
110
Div. Payout %
31%
24%
25%
30%
31%
31%
27%
27%
44%
50%
36%
31%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
27
53
53
53
53
53
53
53
53
53
53
53
Reserves
3,469
4,240
5,304
5,872
6,904
7,257
9,242
11,675
12,714
13,518
14,916
16,708
Borrowings
27
42
36
63
106
39
5
4
3
3
4
7
Other Liabilities
883
562
762
797
973
1,183
1,471
1,628
1,654
1,886
1,948
3,251
Total Liabilities
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
Fixed Assets
1,309
1,439
1,559
1,996
2,088
2,782
3,704
4,325
4,723
4,739
5,442
6,528
CWIP
218
264
444
120
492
920
711
470
212
778
1,022
2,113
Investments
733
803
1,631
1,889
1,946
971
0
72
77
82
65
69
Other Assets
2,145
2,392
2,521
2,780
3,511
3,858
6,356
8,493
9,413
9,861
10,392
11,309
Total Assets
4,405
4,898
6,155
6,785
8,036
8,531
10,771
13,360
14,425
15,460
16,921
20,019
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
826
1,038
1,150
776
954
1,216
1,947
1,912
2,460
1,261
1,653
2,738
Investing
-521
-406
-1,140
-478
-685
-83
75
-2,195
-2,708
-269
-804
-2,219
Financing
-303
-631
2
-314
-246
-1,091
-35
-532
-797
-799
-799
-804
Net Cash Flow
3
0
13
-17
23
41
1,987
-816
-1,045
193
50
-285
Free Cash Flow
519
642
774
502
221
33
1,037
1,199
1,987
258
215
221
CFO/OP
88
91
100
82
77
91
90
66
124
74
83
105
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
85
81
95
86
96
88
99
84
100
106
103
Inventory Days
350
293
307
314
347
316
329
341
352
364
311
346
Days Payable
68
56
104
96
96
100
117
96
89
94
88
106
Cash Conversion Cycle
368
322
284
313
336
312
300
344
347
370
330
343
Working Capital Days
140
158
147
176
169
180
152
177
188
206
192
195
ROCE %
33%
36%
29%
22%
29%
25%
32%
35%
19%
16%
20%
22%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Divis Laboratories insights

68 extracted metrics + investor summaries across FY06–FY27.

Log in — free

Shareholding Pattern

Others2.13%Promot.51.88%Public6.41%DIIs19.38%FIIs20.20%As ofJun 2026

Documents

Frequently Asked Questions about Divis Laboratories

What does Divis Laboratories Ltd do?
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
Where is Divis Laboratories Ltd (DIVISLAB) listed?
Divis Laboratories Ltd trades as DIVISLAB on the NSE and under code 532488 on the BSE.
Which sector does Divis Laboratories Ltd belong to?
Divis Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Divis Laboratories Ltd?
Divis Laboratories Ltd has a market capitalisation of ₹2,45,426 Cr, which places it in the Large Cap band.
What is the PE ratio of Divis Laboratories Ltd?
Divis Laboratories Ltd trades at a PE ratio of 83.94, on earnings per share of ₹63.06, against a book value of ₹631.38 per share.
What is the 52-week high and low of Divis Laboratories Ltd?
Over the last 52 weeks Divis Laboratories Ltd has traded between ₹5,647.5 and ₹9,740.
Does Divis Laboratories Ltd pay dividends?
Divis Laboratories Ltd has a dividend yield of 0.32%.
What is the Return on Equity (ROE) of Divis Laboratories Ltd?
Divis Laboratories Ltd reported a return on equity of 15.32%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Website divislabs.com
CEO Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Employees 10,542
Listed 2003-03-12
Face Value ₹ 2
Issued Size 26,54,68,580

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DIVISLAB.md for Divis Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List